Yusuke Nakamura to Neoplasms
This is a "connection" page, showing publications Yusuke Nakamura has written about Neoplasms.
Connection Strength
4.869
-
Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J Transl Med. 2022 05 23; 20(1):241.
Score: 0.298
-
Integrative cancer genomics in the era of precision cancer medicine. J Hum Genet. 2021 09; 66(9):843.
Score: 0.282
-
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
Score: 0.282
-
Immunogenomics in personalized cancer treatments. J Hum Genet. 2021 Sep; 66(9):901-907.
Score: 0.280
-
The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Jpn J Clin Oncol. 2019 Jul 01; 49(7):596-603.
Score: 0.244
-
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018 Mar; 109(3):542-549.
Score: 0.222
-
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol Sci. 2017 01; 38(1):15-24.
Score: 0.203
-
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Oncotarget. 2016 Apr 05; 7(14):18171-82.
Score: 0.195
-
Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci. 2016 Apr; 107(4):377-84.
Score: 0.193
-
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15.
Score: 0.192
-
Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug; 104(8):1074-82.
Score: 0.160
-
Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
Score: 0.142
-
The BioBank Japan Project. Clin Adv Hematol Oncol. 2007 Sep; 5(9):696-7.
Score: 0.107
-
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005 Oct; 37(10):1104-7.
Score: 0.094
-
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004 Aug; 6(8):731-40.
Score: 0.086
-
Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004 Jan; 95(1):7-11.
Score: 0.083
-
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine. Front Immunol. 2023; 14:1223331.
Score: 0.082
-
Head-to-head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti-FZD10 antibody OTSA101. Cancer Sci. 2023 Dec; 114(12):4677-4690.
Score: 0.082
-
Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002 Jan 15; 62(2):518-27.
Score: 0.073
-
Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021 Sep; 66(9):909-926.
Score: 0.070
-
Clinicopathologic significance of protein lysine methyltransferases in cancer. Clin Epigenetics. 2020 10 13; 12(1):146.
Score: 0.067
-
Diagnostic utility and pitfalls of intraoperative pulmonary imprint cytology based on final pathological diagnoses. Cytopathology. 2019 01; 30(1):74-81.
Score: 0.059
-
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
Score: 0.055
-
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017 May 01; 3(5):636-651.
Score: 0.052
-
Statin use and all-cause and cancer mortality: BioBank Japan cohort. J Epidemiol. 2017 Mar; 27(3S):S84-S91.
Score: 0.052
-
Survival of macrovascular disease, chronic kidney disease, chronic respiratory disease, cancer and smoking in patients with type 2 diabetes: BioBank Japan cohort. J Epidemiol. 2017 Mar; 27(3S):S98-S106.
Score: 0.052
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.049
-
SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells. Oncotarget. 2015 Dec 22; 6(41):43162-71.
Score: 0.048
-
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
Score: 0.048
-
PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Oncotarget. 2015 Nov 03; 6(34):35173-82.
Score: 0.047
-
SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. Oncotarget. 2015 Jul 10; 6(19):16939-50.
Score: 0.046
-
The NSD family of protein methyltransferases in human cancer. Epigenomics. 2015 Aug; 7(5):863-74.
Score: 0.046
-
Guidance for peptide vaccines for the treatment of cancer. Cancer Sci. 2014 Jul; 105(7):924-31.
Score: 0.043
-
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res. 2013 Aug 15; 19(16):4508-20.
Score: 0.040
-
MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. Cell Cycle. 2013 Jun 01; 12(11):1655-6.
Score: 0.040
-
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.
Score: 0.039
-
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer. 2013 Feb; 52(2):126-39.
Score: 0.038
-
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia. 2011 Oct; 13(10):887-98.
Score: 0.036
-
Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet Genomics. 2011 Sep; 21(9):552-8.
Score: 0.035
-
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia. 2011 Aug; 13(8):676-84.
Score: 0.035
-
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer. 2011 May 28; 10:65.
Score: 0.035
-
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011 Jul; 102(7):1298-305.
Score: 0.035
-
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.
Score: 0.034
-
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011 Feb 01; 128(3):574-86.
Score: 0.034
-
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2011 Feb 01; 128(3):562-73.
Score: 0.034
-
Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011 Feb 01; 71(3):655-60.
Score: 0.034
-
Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer. 2010 Sep 01; 127(6):1393-403.
Score: 0.033
-
Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010 Jul 01; 70(13):5326-36.
Score: 0.033
-
The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010 May 01; 126(9):2153-63.
Score: 0.032
-
International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8.
Score: 0.032
-
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet. 2009 Oct; 54(10):572-80.
Score: 0.031
-
Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med. 2009 Jul; 23(5):479-85.
Score: 0.030
-
Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 2007 Sep 15; 67(18):8544-53.
Score: 0.027
-
Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res. 2007 Sep; 6(9):3475-83.
Score: 0.027
-
Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. Mol Ther. 2006 Oct; 14(4):599-606.
Score: 0.025
-
Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene. 2005 Jul 28; 24(32):5131-6.
Score: 0.023
-
Adenovirus-mediated p53AIP1 gene transfer as a new strategy for treatment of p53-resistant tumors. Cancer Sci. 2004 Jan; 95(1):91-7.
Score: 0.021
-
Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci. 2003 Dec; 94(12):1074-82.
Score: 0.021
-
An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002 Feb 15; 62(4):1139-47.
Score: 0.018
-
SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget. 2016 Nov 15; 7(46):75023-75037.
Score: 0.013
-
Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis. Cancer Sci. 2006 Jul; 97(7):633-41.
Score: 0.006